tbuckley/cabot-search huggingface dataset:
SAT0303 Effect of Hmg-Coa Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Authors: G.M. Garcia, A. Urbano, E. Salido
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Statins have a known effect in reducing the morbidity and mortality due to atherosclerosis. Recently, statins have been proposed to have anti-inflammatory and immunomodulatory effects. In in-vitro studies these drugs inhibit inflammatory cells like monocytes, macrophages, and lymphocytes, decrease the expression of major histocompatibility complex (MHC) and decrease adhesion molecules and inflammatory cytokines such as IL6 and IL10, that are also implicated in SLE pathogenesis. In terms of immunomodulary effects, animal studies demonstrated that statins exacerbate or trigger cellular apoptosis and induce a shift in the Th1/Th2 balance leading to B-cell reactivity and production of pathogenic autoantibodies. Also it has been found that Treg cells can be unstable in the periphery and may promote autoimmunity. These may promote preexisting autoimmune conditions to progress toward clinical disease, such as SLE. Statins have not been widely studied in SLE. The existing studies mostly have primary endpoints on the evaluation of atherosclerosis, and in terms of disease activity, these studies showed contradicting results. Thus, we sought to determine the effect of statins on the disease activity of SLE based on the best available evidence. <h3>Methods</h3> To identify relevant publications on statins and SLE disease activity, a systematic literature search of PubMed, Scopus, and Cochrane databases was done with no date and language restrictions. Included studies were on adult SLE patients. Only randomized controlled trials that used statins as intervention and reported SLE disease activity as an outcome measure were included. Two reviewers did quality appraisal, risk bias assessment, and data extraction. <h3>Results</h3> Three studies have met the eligibility criteria and were included in this review. Quantitative synthesis was then done. The pooled analysis of these studies suggests that statins have no significant effect on disease activity on random effects model with an overall effect of 0.13 (P=0.90, 95% CI -1.65, 1.88). <h3>Conclusions</h3> Statins neither increased nor decreased SLE disease activity; therefore possibly it can be safely given to SLE patients without the risk of triggering or exacerbating a flare. <h3>Disclosure of Interest</h3> None declared
PWE-060 Capsule Endoscopy in The Investigation and Management of Small Bowel Crohn’s Disease
Authors: N Zuhra, S Sartain, J Gordon, D Lloyd
Journal: Gut (2016)

<h3>Introduction</h3> Capsule endoscopy (CE) is increasingly being used to visualise the small intestine in patients with known or suspected Crohn’s disease. The aim of this study was to review the use of CE for this purpose over a two year period in a medium sized DGH following the creation of a new CE service. <h3>Methods</h3> Electronic records of all patients undergoing CE between 1<sup>st</sup> April 2013 and 31<sup>st</sup> March 2015 were reviewed. Patients who underwent the procedure to investigate for possible small bowel Crohn’s disease (based on clinical, biochemical and/or endoscopic suspicion) or to assess previously diagnosed Crohn’s disease we identified. Record was also made of contemporaneous faecal calprotectin results and ileal appearances at colonoscopy. <h3>Results</h3> Twenty-four patients underwent CE to investigate possible small bowel Crohn’s disease. Of these, 11 (46%) had CE findings supportive of Crohn’s disease. 5 of these 11 patients had contemporaneous faecal calprotectin measurement of which 4 (80%) were positive. Eight of these 11 patients had contemporaneous ileal intubation of which 7 (88%) showed evidence of ileitis. Of the 13 patients with normal CE findings, 8 had faecal calprotectin measurement of which only 1 (12%) was positive. Eleven of the 13 patients had contemporaneous ileal intubation of which 4 (36%) showed mild ileitis. Ten patients underwent CE to assess known small bowel Crohn’s disease. CE was normal in 4 cases and showed evidence of active small bowel Crohn’s in 6 cases. Of the 4 patients with normal CE findings, 2 had faecal calprotectin measurement of which both were normal and 3 had ileal intubation which showed no evidence of inflammation in all cases. Of the 6 patients with CE findings suggestive of active small bowel Crohn’s, 5 had faecal calprotectin measurement of which 4 (80%) were normal and all 6 had ileal intubation which showed ileitis in 4 (67%). <h3>Conclusion</h3> In patients with suspected small bowel Crohn’s disease CE findings supported this diagnosis in nearly half of patients and CE findings correlated well with faecal calprotectin measurement and ileal appearances at colonoscopy. However, in patients undergoing CE to assess known small bowel Crohn’s, CE showed active disease in 57% of patients with normal faecal calprotectin measurement although there was better correlation between CE findings and ileal appearances at colonoscopy. This suggests that CE is an informative test in both the investigation and ongoing management of small bowel Crohn’s disease, and may be a more sensitive test of small bowel Crohn’s disease than faecal calprotectin. <h3>Disclosure of Interest</h3> None Declared
Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia
Authors: Giovanni Del Poeta, Maria Ilaria Del Principe, Francesca Maria Rossi, Angela Coletta, Francesco Buccisano, Cristina Simotti, Maria Christina Cox, Fabrizio Luciano, Antonella Zucchetto, Luca Maurillo, Annalisa Biagi, Pasquale Niscola, Maria Antonietta Irno Consalvo, Alessio Pio Perrotti, Adriano Venditti, Paolo de Fabritiis, Valter Gattei, Sergio Amadori
Journal: Blood (2010)
Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,
Authors: Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Usmani, Helgi van de Velde, Xiang Qin, Ming Qi, Mark J. Cornfeld, Frits van Rhee
Journal: Blood (2011)
A Report of AIDS-Related Lymphoma (ARL) in Korea.
Authors: Jin-Soo Kim, Seok Jin Kim, Jin Seok Kim, Yoo Hong Min, Moon Hee Lee, Soo-Mee Bang, Jeong A. Kim, Hyun-Sook Chi, Seong Soo Jang, Chan Jeoung Park, Cheolwon Suh, Chul Soo Kim
Journal: Blood (2006)
Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis
Authors: Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp
Journal: Blood (2010)
SAT0559 The Anatomical Distribution of Inflammation, Fat, Erosion and New Bone Formation in The Spine Assessed According To The Canada-Denmark MRI Definitions in Patients with Axial Spondyloarthritis: Table 1.
Authors: S. Krabbe, M. Østergaard, I.J. Sørensen, B. Jensen, O.R. Madsen, G.P. Eng, K.H. Asmussen, J. Møller, L. Balding, S.J. Pedersen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> On MRI, patients with axial spondyloarthritis (axSpA) demonstrate lesions at several anatomical locations. These locations include the vertebral bodies, e.g. anterior and posterior corners and lesions without relation to the corners, and also the posterior segments of the vertebrae, e.g. the costo-transversal joints, costo-vertebral joints, facet joints, spinous/transverse processes, and surrounding soft tissue. The Canada-Denmark (CanDen) definitions of MRI lesions in the spine allows a detailed evaluation of all these anatomical locations for inflammation, fat, erosions and new bone formation.(1–3) <h3>Objectives</h3> To assess the anatomical location of positive scores by the CanDen MRI scoring system of the spine. <h3>Methods</h3> 49 patients with axial SpA (ASAS criteria) and clinical indication for tumor necrosis factor alpha (TNFα) inhibitor, including BASDAI &gt;40 mm, had MRI of the spine performed at baseline. 51% were male. Median symptom duration (range) was 12 (0–45) years. Images were scored using the CANDEN MRI scoring system by a reader blinded to clinical data. <h3>Results</h3> In total, 10 of 49 patients (20%) had involvement of the costo-transversal joints, facet joints, spinous/transverse processes or soft tissue. <h3>Conclusions</h3> The most frequent lesion in patients with axSpA were inflammation and fat lesions in the rim of the vertebral bodies (the anterior, posterior, antero-lateral and postero-lateral corner lesions) in the thoracic and lumbar spine. 1/5 of the patients had involvement of the posterior segments. <h3>References</h3> Østergaard et al. J Rheumatol 2009;36-S84:18–34 Lambert et al. J Rheumatol 2009;36-S84:3–17 Pedersen et al. J Rheumatol 2009;36-S84:35–38 Chiowchanwisawakit et al. J Rheumatol 2009;36-S84:39–47 <h3>Disclosure of Interest</h3> None declared
Abstract MP76: Severe Hypoglycemia and Prevalence of Cognitive Impairment in Older Adults with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Alexandra K Lee, Andreea M Rawlings, Andrea L Schneider, A R Sharrett, Elbert S Huang, Elizabeth Selvin
Journal: Circulation (2016)

Introduction: Hypoglycemia and cognitive impairment are major problems in older adults with diabetes. It is unknown whether persons with prior hypoglycemia have distinct patterns of cognitive impairment compared to persons without hypoglycemia. Hypothesis: Compared to older adults with diabetes and no history of hypoglycemia, persons with prior hypoglycemia will have worse cognitive performance across all domains, but particularly in the executive function domain. Methods: We conducted a cross-sectional analysis of older adults with diagnosed diabetes using data from the ARIC study (2011-2013). Participants completed eight cognitive tests that measured three domains: memory, language, and executive function. Cognitive impairment in each domain was defined as having at least one test score lower than 1.5 standard deviations below age-, race-, and education-specific norms. We identified prior severe hypoglycemic events through 2012 with ICD-9 codes from hospitalizations and emergency department visits. We used Poisson regression with robust standard errors to generate prevalence ratios (PR) adjusted for demographic and clinical characteristics. Results: Among 1,867 adults with diagnosed diabetes: mean age 76 years, 56% female, 32% black, and 3% with prior hypoglycemia. In persons with prior hypoglycemia, 50% had cognitive impairment in at least one domain, compared to 43% in persons without prior hypoglycemia (p=0.24). After adjustment, persons with prior hypoglycemia were more likely to have worse performance in executive function (PR=1.73; 95% CI: 1.14-2.64) and language (PR=1.78; 95% CI: 1.08-2.93) but not memory (PR=1.19; 95% CI: 0.81-1.76) (Figure). Conclusions: Persons with prior severe hypoglycemia are a unique subset of older adults with diabetes with greater cognitive deficits in the domains of executive function and language. Their cognitive impairment presents challenges for the management of their diabetes and the prevention of additional hypoglycemic episodes and cognitive decline.
Meaning and the Nature of Physicians’ Work
Authors: David I. Rosenthal, Abraham Verghese
Journal: New England Journal of Medicine (2016)

Interview with Dr. David Rosenthal on the effect of the electronic era on physician satisfaction. (07:29)Download Perhaps the greatest opportunity for improving physicians' professional satisfaction in the short term lies in restoring our connections with one another. We will have to rebuild a sense of teamwork, community, and the ties that bind us together as human beings.
OC-077 Does Faecal Occult Blood Testing Help Identify Ileo-Colonic Neuroendocrine Tumours in the UK Bowel Cancer Screening Programme (BCSP)?
Authors: R Basuroy, K O’Donnell, C Brooks, R Srirajaskanthan, J Ramage
Journal: Gut (2016)

<h3>Introduction</h3> There has been an increase in the incidence of ileo-colonic NETs in recent years, partly from endoscopy. There is no published data on the incidence of NETs diagnosed in the UK ‘double’ screen BCSP of initial Faecal Occult Blood stool test (FOBt) and, if abnormal, colonoscopy. The incidence (per 100 k) of colorectal cancer (CRC) in FOBt abnormal UK BCSP colonoscopy is 55 times that of the population incidence (10 k vs 184).<sup>1</sup> The aim of this study was to identify NETs diagnosed and recorded at UK BCSP colonoscopy between 2005–14. <h3>Methods</h3> Data requests were made to UK BCSP for details of screened populations, abnormal FOBts, and colonoscopies performed and CRCs diagnosed. NET related queries were run across 3 database tables; ‘Polyp Histology Polyp Architecture’, ‘Lesion Type’, ‘Histology Snomed’. Incidence (per 100 k) was compared with those from the SEER database;<sup>2</sup> small intestine and colorectal NETs 2.4; rectal 0.9, other colonic 0.4, appendiceal 0.2, small intestine 0.9. <h3>Results</h3> 13 million people completed FOBt screening with 260 k abnormal FOBt and 217 k colonoscopies. 146 NETs were identified with an incidence of 67 (per 100 k colonoscopies). The incidence of NETs (per 100 k colonoscopies) by site was 29 rectal, 18 other colonic, 1 appendiceal, and 11 small intestine. Ratios of BCSP to SEER incidences was 29 overall NET, 32 rectal, 45 other colonic, 5 appendiceal, and 12 small intestine. <h3>Conclusion</h3> The incidence of NETs at UK BCSP colonoscopy following an abnormal FOBt is markedly higher than the SEER population incidence. The effect is greatest for rectal and other colonic NETs although less than that seen with CRC (55 x) following FOBt screening. There is no published data on the incidence of small intestine NETs identified from terminal ileum intubation during ‘single’ or ‘double screen’ BCSP. However, the rectal NET incidence in the UK FOBt BCSP is lower (29 per 100 k colonoscopies) than that published from ‘single screen’ colonoscopy-only BCSP (50–70 per 100 k colonoscopies).<sup>3</sup> This suggests endoscopic screening itself is more helpful than FOBt screening in identifying rectal NETs. <h3>References</h3> 1 Logan RF, Patnick J, Nickerson C, <i>et al</i>. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. <i>Gut</i> 2012;<b>61</b>(10):1439–1446. 2 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumours. <i>Cancer</i> 2003;<b>97</b>(4):934–959. 3 Kaminski M, Polkowski M, Regula J. Prevalence and endoscopic features of rectal neuroendocrine tumours (carcinoids) among 50148 participants of the Polish colorectal-cancer screening programe. <i>Gut</i> 2007;<b>56</b>(Suppl III): A310. <h3>Disclosure of Interest</h3> None Declared
SP0127 Year in Review - Osteoarthritis
Authors: M. Doherty
Journal: Annals of the Rheumatic Diseases (2016)

This talk will highlight, and place into perspective, new research published on osteoarthritis (OA) in the past year. The focus is on studies that significantly contribute to our better understanding of OA or which may influence management of people with OA. Topics with recent key publications that will be included to date are: new genetic data on OA; correlation between symptoms and structural changes of OA; the role of inflammation in OA, including early OA; relationship between calcium crystal deposition and OA; inter-relationships between sleep, fatigue and pain in OA; the use of network meta-analysis to compare different effects sizes of available treatments; the high proportion of contextual effect of OA treatments; and ways to present results of RCTs that may reduce the efficacy paradox. Additional topics may be included depending on publications in Q2 2016. <h3>Disclosure of Interest</h3> None declared
P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD: Abstract P144 Table 1
Authors: S Singh, F Maltais, L Tombs, WA Fahy, M Vahdati-Bolouri, JH Riley
Journal: Thorax (2015)

<h3>Background</h3> The Minimal Clinically Important Difference (MCID) for pharmacotherapy for the endurance shuttle walking test (ESWT) has been reported by Pepin <i>et al</i>.<sup>1</sup> Two performance measures, change in time (45– 85 s), and percentage change from baseline (13–15%) are investigated here. <h3>Objective</h3> To review endurance outputs in two exercise studies combined in this post-hoc analysis, and compare two different measures of performance MCID, exercise time in seconds and as a percentage change. <h3>Methods</h3> The effect of umeclidinium (UMEC 62.5 mcg)/vilanterol (VI 25 mcg), VI (25 mcg) and UMEC (62.5 mcg) compared with placebo on exercise endurance, using the ESWT across two 12-week cross-over studies enrolling hyperinflated COPD patients (FRC &gt;120%) was investigated. All ESWTs were performed at 80% VO<sub>2</sub> max derived from a baseline incremental SWT. ESWT time (in seconds) and% change from baseline were reported and compared at Day 2 and 84, 3 h post-dose. Analysis was performed using a repeated measures model with covariates of study, period walking speed, mean walking speed, period, treatment, visit, smoking status, centre group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. <h3>Results</h3> Baseline exercise endurance times (EET) and on-treatment change from baseline as seconds and percentage are presented in Table 1. UMEC/VI showed mean changes (95% CI) from placebo at Day 2 of 53.0s (33.4, 72.6) and 18.4% (10.1, 26.8) both p &lt; 0.001 and at Day 84 of 43.7s (15.5, 72.0) p = 0.002 and 16.4% (4.8, 27.9) p = 0.005. Adverse events were similar between treatments. <h3>Conclusions</h3> UMEC/VI was associated with improvements in both measures of exercise endurance, as were UMEC and VI to a lesser magnitude. An improvement greater than the MCID for percentage change from baseline was observed for UMEC/VI vs placebo at both timepoints, whereas for change from baseline EET only the Day 2 analysis vs placebo showed a result greater than the MCID. MCID as percentage change from baseline may be a more meaningful measure of response to bronchodilators than MCID in seconds because it reflects a patient’s baseline exercise tolerance. No additional safety concerns were identified. <h3>Funding</h3> GSK Clinicaltrials.gov: NCT01328444, NCT01323660 <h3>Reference</h3> 1 Pepin V, <i>et al</i>. <i>Thorax</i> 2011;<b>66</b>(2):115–20
Genome Wide Association Studies of Familial Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in Families with a History of B-Cell Disorders but Not in Those with a History Specific for WM.
Authors: Zachary Hunter, Christina Hanzis, Thea Ioakimidis, Christopher J Patterson, Bryan Ciccarelli, Megan Lewicki, Robert Manning, Lian Xu, Xia Liu, Hsiuyi Tseng, Ping Gong, Jenny Sun, Yangsheng Zhou, Guang Yang, Patricia Sheehy, Edward A. Fox, Steven Treon
Journal: Blood (2009)
AB0946 S100A8 but Not S100A9 Level Is Related To The Extent of Erosive Bone Damage in Psoriatic Arthritis Patients
Authors: D. Simon, K. Nas, F. Faustini, A. Kleyer, J. Haschka, M. Englbrecht, A.J. Hueber, R. Kocijan, M. Sticherling, G. Schett, J. Rech
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriasis and psoriasis arthritis are associated with bone damage [1–3]. However, little is known about markers associated with structural bone damage in patients with psoriasis (PsO) and psoriasis arthritis (PsA). C-reactive protein is of limited use in PsO and PsA and therefore development of new markers is needed to identify patients with higher level structural bone damage. The calcium-binding proteins S100A8 and S100A9, which are predominantly produced by myeloid cells and elevated in certain forms of inflammatory diseases are interesting candidates. <h3>Objectives</h3> To analyse whether S100A8 and S100A9 serum levels are related to structural bone damage in patients with PsO and PsA. <h3>Methods</h3> Both PsO and PsA patients (according to the CASPAR criteria) were analysed. Demographic and disease-specific variables were recorded. Bone architecture was assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT, XtremeCT, Scanco, Switzerland) of the metacarpal heads 2 and 3. Number and size of bone erosions were quantified as described previously [1]. Levels of S100A8 and S100A9 were measured by enzyme-linked immunosorbent test. Serum markers were correlated to the extent (volume) of bone erosions, respectively using Spearmans correlation. <h3>Results</h3> 94 patients were included into this combined imaging and serum analysis, 42 of them had PsO (18 female, mean age 48.4±12.8 years) and 52 had PsA (29 female, age 48.3±14.8 years). Duration of skin disease was 14.7±16.1 years in PsO and 13.3±13.6 years in PsA. Duration of joint disease in PsA was 4.6±5.9 years. Mean time between blood collection and HR-pQCT measurement was 0.3±1.7 days (maximum 10 days). Mean±SD S100A8 level was 11.8±15.3 ng/ml in PsO patients and 12.8±13.8 ng/ml in PsA, while mean ±SD S100A9 level was 66.8±51.1 ng/ml in PsO and 75.9±58.3 ng/ml in PsA. Mean±SD erosion volume was 0.7±1.8 mm<sup>3</sup> in PsO patients and as high as 2.2±3.6 mm<sup>3</sup> in PsA. Serum levels of S100A8 were significantly correlated to erosion volumes (<i>ρ</i>=0.327 (p=0.019)) in PsA but not in PSO. No significant correlation for S100A9 was found. <h3>Conclusions</h3> S100A8 but not S100A9 level is significantly correlated to the extent of structural bone damage in patients with PsA. Hence, S100A8 may emerge as an interesting biomarker for determining the severity of psoriatic disease, especially the extent of structural bone damage. <h3>References</h3> Simon D, et al. Ann Rheum Dis 2014;73:464–5. Finzel S, et al. Ann Rheum Dis. 2011;70:122–7. Kocijan R, et al. J Bone Miner Res. 2015;30:1775–83. <h3>Disclosure of Interest</h3> None declared
Analysis of CD4+CD25hi Regulatory T Cells in the Peripheral Blood of Patients with B Cell Chronic Lymphocytic Leukemia (CLL).
Authors: Vassiliki Pappa, Vassiliki Giannopoulou, Katerina Spyridaki, Vassiliki Karayanni, Elisabeth Liakata, Frieda Kontsioti, Evangelos Giamarelos, Efstathios Papageorgiou, John Dervenoulas, Theofanis Economopoulos
Journal: Blood (2007)
Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Authors: Brad S. Kahl, James McGovern, Jules Blank, Anthony Jaslowski, Gerald Bayer, Wayne A. Bottner, Hamied Rezazadeh, Thomas McFarland, David Hei, Jamie Smith, Emily A. Stevens, Jens C. Eickhoff, Walter L. Longo
Journal: Blood (2004)
SP0058 Scoring Osteoarthritis (OA)
Authors: I. Möller
Journal: Annals of the Rheumatic Diseases (2016)

Musculoskeletal ultrasound (US) is an imaging tool applicable in the detection and scoring of elementary lesions in patients with knee and hand OA. After defining and reaching a consensus on the US detected elementary lesions in patients with hand and knee OA, the reliability of the agreed scoring system has been tested. In both cases, using semi-quantitative and/or dichotomous scales, the results showed moderate to good reliability. The results vary depending on the elementary lesion tested. For example, there was good reliability for osteophyte scoring in hand OA but fair to moderate for cartilage with intermediate degrees of damage according to the proposed scoring systems. Other joints will be tested in the future with the purpose of assessing reliability of the scoring these elementary OA lesions. <h3>Disclosure of Interest</h3> None declared
Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases
Authors: Jijun Liu, Ling Zhang, Ernesto Ayala, Teresa Field, Jose L. Ochoa-Bayona, Lia Perez, Celeste M. Bello, Paul A. Chervenick, Salvador Bruno, Eduardo M. Sotomayor, Lubomir Sokol
Journal: Blood (2010)